СРАВНЕНИЕ ТОКОЛИЗА ГЕКСОПРЕНАЛИНОМ И АТОЗИБАНОМ

Медицинский совет

Н. К. Тетруашвили¹  З. С. Ходжаева¹  О. Н. Васильченко¹  О. Р. Баев¹  А. О. Карапетян¹ 

[1] Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России;

关键词: premature labor;    tocolysis;    atosiban;    hexoprenaline;   

DOI  :  10.21518/2079-701X-2017-2-57-61

来源: DOAJ

【 摘 要 】

The aim of the study was to compare the efficacy and safety of tocolytic agents - atosiban and hexoprenaline.Patients and methods: The study included 119 pregnant women with threatening preterm labour between 28 to 34 weeks of gestation. Sixty two pregnant received 62 tocolysis by hexoprenaline and fifty seven - atosiban. There were no differences in the clinical condition of pregnant women and features of preterm labour among groups before start of the tocolysis.The degree of effectiveness is determined by the duration of the pregnancy prolongation (48 hours, 7 days, more than 14 days).Results: 9 women of 62 that received hexoprenaline tocolysis (22,6%), and 2 – atosiban (3.5%) failed to prolong the pregnancy for more than 48 hours (p < 0,05). Additionally, 5 women of the hexoprenaline group had premature labour within the first week from the treatment start and eight within 7-14 days. In the group of women with an effective atosiban tocolysis all births took place in a range of more than 7 days from the beginning of tocolysis. Four woman in hexoprenaline group received one repeated course of therapy with this drug (without a loading dose) for 24 hours. In atosiban group full repeated course was conducted in the two cases. Full-term gestation births occurred in 14 women (22.6%) after hexoprenaline tocolysis and in 19 (33.3%) – atosiban (p > 0,05%). On average, atosiban tocolysis allowed to prolong pregnancy by 6.5 days longer than hexoprenaline (p < 0,05).Conclusion: The results of study has shown that atosiban is more effective than hexoprenaline in pregnancy prolongation for more than 48 hours in threatening preterm labor.

【 授权许可】

Unknown